BIA Networking Breakfast - Cambridge

Steve Bates OBE

Chief Executive Officer

What does your role at BIA involve?

Steve Bates is the CEO of the UK Bioindustry Association, the UK’s Trade Association for innovative life science companies with over 550 members. Steve is the visible face of the vibrant UK life sciences industry to government and media. He serves on the UK Government’s Life Sciences Council and the UK Biosecurity Leadership Council. Steve was a founder member of the UK Government’s Vaccine Taskforce in the Covid crisis, sitting on its steering Board alongside Kate Bingham. He is active member and former chair the International Council of Biotech Associations and has been a board member of EuropaBio since 2015.

Previous experience & achievements

Steve has championed, with government, effective industrial incentives like the Biomedical Catalyst, which have crowded in private sector investment into UK SMEs. He is a driving force behind the scale up agenda, spearheading policy agenda to unlock UK pension fund capital into productive UK growth in life sciences. He has forged several links for the sector across the USA, Europe and in China. In his time at the BIA, Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before joining the BIA in 2012, Steve worked for Genzyme and was advisor to the UK Government of Tony Blair working on NHS reform and the Northern Ireland peace process. He was made OBE for services to innovation in 2017 and became a Fellow of the Academy of Medical Science in 2020.

Nicola Baker-Munton

Chief Executive Officer, Stratagem IPM

Nicola Baker-Munton is the founder and Chief Executive Officer of Stratagem IPM. She is a Chartered UK Patent Attorney and European Patent Attorney with a joint honours degree in biology and biochemistry. During her nine years as an industrial practitioner at the Wellcome Foundation Limited, and four years in the private sector, Nicola recognised the need for much greater assistance with management of intellectual property earlier in the development of technologies, and advice and assistance with commercialisation throughout the technology/product life-cycle. Nicola founded Stratagem IPM in 1999. With Steady growth it has become the leading specialist company providing active strategic management of intellectual property portfolios from inception through development to market, and from academia through startup to stock market listing.

Jane Dancer

Chair, Spirea, PharmEnable and Elasmogen

Jane has over 30 years’ experience in the life science industry across biotech, pharma and agrochemicals. She is currently Chair of Spirea, PharmEnable and Elasmogen and an NED at Macomics and Nanosyrinx. Her past roles include Chief Business Officer at F-star, Vice President of Business Development at Cellzome, and Director of Business Development at Astra Zeneca (formerly Cambridge Antibody Technologies). The first part of her career was spent in the agrochemical industry in research and project management. Jane holds an MA and PhD in Natural Sciences from Cambridge University, as well as an MBA from the Cambridge Judge Business School.

Dr Tony Jones

CEO, One Nucleus

Dr Anker Lundemose

Chief Executive Officer, Mission Therapeutics

In a biopharma career spanning over twenty five years, Dr. Lundemose brings extensive international experience in areas of management, business and corporate development, M&A strategy, and execution, financing, as well as R&D in key therapeutic areas including oncology, neuroscience, diabetes, obesity and anti-infectives. He is an entrepreneur and founder of several successful biotech companies. He is on the board of Inthera Therapeutics and Antag Therapeutics. Prior to Mission Therapeutics, Dr. Lundemose was CEO of publicly listed Bionor Pharma, and owner and Managing Partner of BioTesch Advice & Consultancy. Previously he was co-founder and CEO of Prosidion, the UK spin-out of OSI Pharmaceuticals’ diabetes and obesity assets, which was reversed into OSI Pharmaceuticals, Inc. At OSI Pharmaceuticals, Dr. Lundemose held several senior management roles, most latterly as Executive Vice President Corporate Development & Strategy Officer, OSI, New York. He was responsible for the acquisition of the DP-IV patent estate from Probiodrug generating 30 times return on investment. He was also involved in the sale of OSI Pharmaceuticals to Astellas Pharma for $4 billion. Dr. Lundemose has been involved in six biotech exits/IPOs and has held Board positions on over 12 Biotech Companies. Dr. Lundemose is a qualified medical doctor and has a D.M.Sc and a Ph.D from the University of Aarhus, Denmark.